AstraZeneca

News

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly are closing the gap with a positi

News

AstraZeneca beats expectations in Q2, while GSK struggles du...

AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic.

News

Trial shows AZ's Farxiga slows onset of chronic kidney disea...

AstraZeneca's Farxiga could be on course for another use, after trial results showed it slowed the worsening of renal function and cut the risk of death in patients with chronic kidney dise

News

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion.

News

AZ's COPD triple therapy approved in the US

AstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the US following a re

News

Controversy as pharma execs predict profits from COVID-19 va...

Concerns have emerged about access to some potential COVID-19 vaccines after pharma executives from three companies said they expect to make profits from their products in evidence to a US

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

AstraZeneca beats expectations in Q2, while GSK struggles du...

Trial shows AZ's Farxiga slows onset of chronic kidney disea...

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

AZ's COPD triple therapy approved in the US

Controversy as pharma execs predict profits from COVID-19 va...

Andexxa reaches the end of the line in the US

How to meet your physicians where they are online

AstraZeneca

Editor's Picks